This review will focus on the mechanism of action of anti-CTLA-4 mAB alone and in combination with other therapies in BC, current clinical trials with anti-CTLA-4 in BC patients, and novel therapeutic approaches to enhance the efficacy and minimize the toxicity of anti-CTLA-4 in BC patients. This evidence concerns the gene CTLA4 and breast cancer.